Tiliroside is a new potential therapeutic drug for osteoporosis in mice

Area of Science:

• Biochemistry
• Pharmacology
• Bone Biology

Background:

• Osteoporosis is a metabolic bone disease characterized by increased osteoclast activity, particularly in postmenopausal women due to estrogen decline.
• Inhibiting osteoclast formation and function is a key therapeutic strategy for osteoporosis.
• Tiliroside (Tle), a flavonoid from Oriental Paperbush, has known anti-inflammatory effects, but its impact on bone metabolism was unexplored.

Purpose of the Study:

• To investigate the effects of Tiliroside (Tle) on osteoclastogenesis and bone resorption.
• To determine if Tle can prevent bone loss in an in vivo osteoporosis model.
• To elucidate the molecular mechanisms underlying Tle's action on osteoclast differentiation.

Main Methods:

• Ovariectomy mouse model was used to induce bone loss.
• In vitro studies assessed Tle's inhibition of osteoclast differentiation and bone resorption stimulated by receptor activator of nuclear factor-κB ligand (RANKL).
• Molecular analyses examined Tle's impact on RANKL-mediated signaling pathways (MAPK, NFATc1) and osteoclast-related gene expression (Ctsk, MMP9, Acp5, Atp6v0d2), as well as reactive oxygen species (ROS) generation.

Main Results:

• Tiliroside (Tle) treatment prevented bone loss in ovariectomized mice.
• Tle significantly inhibited RANKL-induced osteoclast differentiation and bone resorption in vitro.
• Tle suppressed RANKL-mediated activation of MAPK and NFATc1 pathways, reduced expression of key osteoclastogenesis genes, and decreased intracellular ROS generation.

Conclusions:

• Tiliroside (Tle) effectively suppresses osteoclastogenesis and mitigates bone loss.
• Tle's mechanism involves downregulating RANKL-mediated signaling and reducing reactive oxygen species.
• Tiliroside shows promise as a potential therapeutic agent for osteolytic diseases like osteoporosis.